Last updated: May 26, 2026
ERIBULIN MESYLATE Suppliers and Supply Chain: API, Intermediates, Fill-Finish, and Commercial Sources
Executive summary: Eribulin mesylate supply is typically sourced through a small set of global manufacturers covering (1) the active pharmaceutical ingredient (API) and/or key intermediates, (2) solid dosage manufacturing (drug substance-to-drug product conversion), and (3) packaging and distribution under license agreements with brand holders and distributors. In practice, procurement is structured around “approved suppliers” maintained by the branded manufacturers and their quality systems, with third-party logistics for cold-chain only where required by the final presentation.
Note: A complete, accurate supplier list with named companies, site addresses, product lines (API vs. finished drug), and current qualification status requires Orange Book-linked product-to-manufacturer mapping and current drug master file (DMF) or CEP/WO registrations, which are not available in the provided input.
Which companies supply eribulin mesylate API and drug substance?
Featured snippet answer: Eribulin mesylate API and drug substance are supplied by licensed API manufacturers that file or reference DMFs/EDMFs and are qualified by the finished-dose manufacturers. Supplier identification is usually determined by Orange Book applicant/labeler mapping and by DMF/EDMF ownership and cross-references.
Common supplier categories for eribulin mesylate
- API manufacturers (drug substance): Sell eribulin mesylate or eribulin (base) plus conversion to mesylate salt as part of the drug substance package.
- Intermediate suppliers: Provide key synthetic building blocks used to build the macrocyclic/complex core, often under tight change-control.
- CDMO solid dosage manufacturers: Convert drug substance into injection-ready presentations, including compounding, aseptic filling, stopper/cap sealing, labeling, and serialization.
What intermediates are used to manufacture eribulin mesylate and who supplies them?
Featured snippet answer: Eribulin mesylate manufacturing requires complex, multi-step intermediates tied to the proprietary synthesis route. Intermediate suppliers are typically engaged under NDA with controlled specifications and limited disclosure in public documentation.
How intermediate supply affects qualification
- Specifications for impurity profiles and residual solvents drive supplier selection.
- Scale-up capability and comparability data influence tech-transfer acceptance.
- Change-control approval timelines can delay qualification for new vendors.
Who supplies eribulin mesylate for US branded products and distributors?
Featured snippet answer: In the US, commercial distribution is tied to the FDA-listed “applicant” and “labeler of record” for the specific NDC presentations, with manufacturing performed at FDA-registered sites and distributed through brand-holder networks and wholesalers.
What procurement teams actually use
- NDC to labeler mapping (for finished-dose sourcing)
- Manufacturing site lists from facility inspections and registration databases
- Quality agreements covering deviations, change notifications, and batch release rules
What contract manufacturing roles exist in eribulin mesylate supply (CDMO fill-finish)?
Featured snippet answer: Many finished-dose supply chains rely on contract manufacturing organizations (CMOs/CDMOs) for sterile compounding and aseptic fill-finish rather than brand-holder in-house operations.
Typical fill-finish scope for injectable cytotoxics
- Aseptic compounding of eribulin mesylate injection concentrates or drug product formulations
- Sterile filtration (as applicable), container closure system verification
- Aseptic processing under cGMP with validated sterilization and environmental monitoring
- Serialization and packaging artwork and compliance labeling
How do Orange Book and DMF status affect identifying eribulin mesylate suppliers?
Featured snippet answer: Supplier identification is anchored to FDA listings (Orange Book for NDA-drug products and related references) and to DMF/EDMF ownership for API and key intermediates. Without those linked identifiers, public-facing “supplier lists” are incomplete.
Why “supplier” and “manufacturing site” differ
- The supplier often holds the DMF (API or intermediate).
- The manufacturer of record often performs formulation and sterile fill-finish.
- The labeler can be different from both supplier and manufacturer due to licensing and distribution structures.
Which supplier constraints matter most for eribulin mesylate availability?
Featured snippet answer: Eribulin mesylate supply constraints are dominated by high complexity synthesis, impurity control, aseptic manufacturing capacity, and sterile packaging line availability.
Procurement risk drivers
- Short list of qualified sterile injectables capacity for cytotoxics
- Tight impurity acceptance windows for complex API routes
- Lead time for container closure systems and sterile filtration components
- Batch release testing capacity (sterility, endotoxin, particulates as applicable)
What regional suppliers exist for eribulin mesylate (US, EU, ROW)?
Featured snippet answer: Supplier footprints vary by region because of NDA/NDS requirements, qualified manufacturing sites, and local distribution relationships. A manufacturer qualified for the EU market may not supply the US presentation, and vice versa.
EU vs US qualification dynamics
- Different inspection histories and batch release testing expectations
- Variation in packaging format and NDC vs EU/UK labeling requirements
- Different DMF reference regimes and regulatory documentation structures
How strong is the eribulin mesylate supply base (single-source vs multi-source)?
Featured snippet answer: For complex sterile oncology injectables, the supply base is often multi-source for sterile fill-finish but can be single-source or near-single-source for specific API routes due to IP, impurity profiles, and tech-transfer barriers.
Signals used to assess supply resilience
- Number of registered manufacturing sites for the relevant dosage form
- Number of approved labelers and NDCs for the same strength/presentation
- Evidence of multiple validated fill-finish lines supporting commercial throughput
What generic or biosimilar supply changes could affect eribulin mesylate supplier landscape?
Featured snippet answer: Generic entry can add finished-dose manufacturers but does not automatically diversify the API supplier base. The key shift usually occurs at drug product manufacturing and packaging level first, with API sourcing following only if qualification and DMF references allow.
Paragraph IV and ANDA timing relevance
- New suppliers typically wait for ANDA approval and process validation acceptance.
- API sourcing shifts only after bioequivalence comparability and impurity profile alignment are accepted.
Key Takeaways
- Eribulin mesylate supply is best analyzed by mapping NDC labeler/manufacturer-of-record to FDA-registered sites and then linking those sites to API/DMF owners.
- Public “supplier lists” are not reliable without Orange Book-linked product mapping and DMF/EDMF ownership data.
- Supply resilience depends on complex API synthesis and sterile injectable fill-finish capacity, not only on the number of distributors.
FAQs
- How can I identify the manufacturer-of-record for a specific eribulin mesylate NDC?
- Do eribulin mesylate generics change the API supplier list or only drug product manufacturing?
- What certifications and quality agreements are typically required to qualify a new eribulin mesylate API supplier?
- Which packaging and container-closure considerations most affect sterile injectable supply for eribulin mesylate?
- How do DMF cross-references determine whether an alternate eribulin mesylate API supplier can be used in an ANDA?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
